Epilepsy Research
Volume 91, Issue 1 , Pages 10-19 , September 2010

A comparison of pregabalin, lamotrigine, and placebo as adjunctive therapy in patients with refractory partial-onset seizures

  • Michel Baulac

      Affiliations

    • Hopital Pitié-Salpêtrière, APHP, Universite PARIS VI and INSERM UMR_S 975, Cortex & Epilepsy, Clinique Neurologique, Hopital de la Pitié-Salpêtrière, Paris, France
    • On behalf of the A008112 Investigators, see Appendix A.
    • Corresponding Author InformationCorresponding author at: Clinique Neurologique, Hopital de la Pitié-Salpêtrière, 47 Bld de l’Hopital, 75013 Paris, France. Tel.: +33 14 216 1811; fax: +33 14 424 5247.
    • ,
  • Teresa Leon

      Affiliations

    • Pfizer Inc., New York, NY, United States
    • On behalf of the A008112 Investigators, see Appendix A.
    • ,
  • Terence J. O’Brien

      Affiliations

    • Department of Medicine, Royal Melbourne and Western Hospitals Melbourne, The University of Melbourne, Parkville, Victoria, Australia
    • Department of Surgery, Royal Melbourne and Western Hospitals Melbourne, The University of Melbourne, Parkville, Victoria, Australia
    • Department of Neurology, Royal Melbourne and Western Hospitals Melbourne, The University of Melbourne, Parkville, Victoria, Australia
    • On behalf of the A008112 Investigators, see Appendix A.
    • ,
  • Edward Whalen

      Affiliations

    • Pfizer Inc., New York, NY, United States
    • On behalf of the A008112 Investigators, see Appendix A.
    • ,
  • Jeannette Barrett

      Affiliations

    • Pfizer Inc., New York, NY, United States
    • On behalf of the A008112 Investigators, see Appendix A.

Received 30 November 2009 ,Revised 5 May 2010 ,Accepted 16 May 2010.

References 

  1. Arroyo S, Anhut H, Kugler AR, Lee CM, Knapp LE, Garofalo EA, et al. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose–response study in adults with partial seizures. Epilepsia. 2004;45:20–27
  2. Beydoun A, Uthman BM, Kugler AR, Greiner MJ, Knapp LE, Garofalo EA. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology. 2005;64:475–480
  3. Biton V, Sackellares JC, Vuong A, Hammer AE, Barrett PS, Messenheimer JA. Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic–clonic seizures. Neurology. 2005;65:1737–1743
  4. Brodie MJ, Wilson EA, Wesche DL, Alvey CW, Randinitis EJ, Posvar EL, et al. Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy. Epilepsia. 2005;46:1407–1413
  5. Elger CE, Brodie MJ, Anhut H, Lee CM, Barrett JA. Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study. Epilepsia. 2005;46:1926–1936
  6. Fleiss JL. Statistical Methods for Rates and Proportions. New York, NY: Wiley Interscience; 1981;
  7. French JA, Kugler AR, Robbins JL, Knapp LE, Garofalo EA. Dose–response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology. 2003;60:1631–1637
  8. Gilliam F, Vazquez B, Sackellares JC, Chang GY, Messenheimer J, Nyberg J, et al. An active-control trial of lamotrigine monotherapy for partial seizures. Neurology. 1998;51:1018–1025
  9. GlaxoSmithKline (2007). LAMICTAL® (lamotrigine) Tablets [prescribing information], Research Triangle Park, NC.
  10. Jawad S, Richens A, Goodwin G, Yuen WC. Controlled trial of lamotrigine (Lamictal) for refractory partial seizures. Epilepsia. 1989;30:356–363
  11. LaRoche SM, Helmers SL. The new antiepileptic drugs: scientific review. JAMA. 2004;291:605–614
  12. Lindberger M, Alenius M, Frisen L, Johannessen SI, Larsson S, Malmgren K, et al. Gabapentin versus vigabatrin as first add-on for patients with partial seizures that failed to respond to monotherapy: a randomized, double-blind, dose titration study. GREAT Study Investigators Group. Gabapentin in Refractory Epilepsy Add-on Treatment. Epilepsia. 2000;41:1289–1295
  13. Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369:1016–1026
  14. Marson AG, Williamson PR, Clough H, Hutton JL, Chadwick DW. Carbamazepine versus valproate monotherapy for epilepsy: a meta-analysis. Epilepsia. 2002;43:505–513
  15. Matsuo F, Bergen D, Faught E, Messenheimer JA, Dren AT, Rudd GD, et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U.S. Lamotrigine Protocol 0.5 Clinical Trial Group. Neurology. 1993;43:2284–2291
  16. Messenheimer J, Ramsay RE, Willmore LJ, Leroy RF, Zielinski JJ, Mattson R, et al. Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial. Epilepsia. 1994;35:113–121
  17. Ryvlin P. Defining success in clinical trials – profiling pregabalin, the newest AED. Eur. J. Neurol. 2005;12(Suppl. 4):12–21
  18. Steel RG, Torrie JH. Principles and Procedures of Statistics. New York, NY: McGraw-Hill Companies; 1960;
  19. Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007;73:137–150

PII: S0920-1211(10)00124-5

doi: 10.1016/j.eplepsyres.2010.05.008

Epilepsy Research
Volume 91, Issue 1 , Pages 10-19 , September 2010

Article Tools

* Image Usage & Resolution